
**SECOND EDITION** 

# HANDBOOK OF MODERN PHARMACEUTICAL ANALYSIS

Edited by Satinder Ahuja and Stephen Scypinski





SEPARATION SCIENCE AND TECHNOLOGY
VOLUME 10
Series Editor Satinder Abuia





# HANDBOOK OF MODERN PHARMACEUTICAL ANALYSIS 2nd Edition

Edited by

#### Satinder Ahuja

Ahuja Consulting Calabash, NC, USA

# Stephen Scypinski

Analytical Research & Development, Bristol-Myers Squibb Company New Brunswick, NJ, USA



AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier





Academic Press is an imprint of Elsevier 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA 84 Theobald's Road, London WC1X 8RR, UK Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands

First edition 2001 Second edition 2011

Copyright © 2011 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any No part of this publication may be reproduced, stored in a stored in a stored in the prior written permission of the means electronic, mechanical, photocopying, recording, or otherwise without the prior written permission of the publisher

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK; phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; e-mail: permissions@elsevier.com. Alternatively you phone (+44) (0) 1865 843830; tax (+44) (0) 1865 853535, change phone (+44) (0) 1865 843830; tax (+44) (0) 1865 84380; tax (+44) (0) 18 Obtaining permission to use Elsevier material.

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence, or otherwise or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made

#### Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

#### British Library Cataloguing in Publication Data

A catalogue record for this book is available from the British Library

ISBN: 978-0-12-375680-0

ISSN: 0149-6395

For information on all Academic Press publications visit our website at www.books.elsevier.com

Printed and bound by CPI Group (UK) Ltd, Croydon, CR0 4YY

Transferred to digital print 2012

Working together to grow libraries in developing countries

www.elsevier.com | www.bookaid.org | www.sabre.org

ELSEVIER BOOK AID Sabre Foundation



# CONTENTS

# PREFACE xi CONTRIBUTORS xiii

## I. Overview of Modern Pharmaceutical Analysis

#### SATINDER AHUJA

- I. Introduction 1
- II. Solid-State Studies 3
- III. Degradation and Impurities Studies 3
- IV. Analytical Considerations for Genotoxic and Other Impurities 4
- V. Quality by Design and Process Analytical Technology 4
- VI. Novel Dosage Forms 4
- VII. Method Development for Chiral Compounds 5
- VIII. Characterization and Analysis of Biopharmaceutical Proteins 5
- IX. Preformulation and Early Phase Method Development 6
- X. In-Process Control Testing 6
- XI. Method Validation 7
- XII. Stability Studies 7
- XIII. Method Transfer 7
- XIV. Documentation 8
  - References 9



٧

# 2. Characterization of Pharmaceutical Compounds in the Solid State

HARRY G. BRITTAIN

- I. Introduction 11
- II. Properties Associated with the Molecular Level 13
- III. Properties Associated with the Particulate Level 26
- IV. Properties Associated with the Bulk Level 36
- V. Summary and Conclusions 49 References 49

## 3. Degradation and Impurity Analysis for Pharmaceutical Drug Candidates

KAREN M. ALSANTE, STEVEN W. BAERTSCHI, MICHAEL COUTANT, BRIAN L. MARQUEZ, THOMAS R. SHARP, AND TODD C. ZELESKY

- I. Forced Degradation Studies 60
- II. Isolation of Impurities/Degradants 80
- III. Mass Spectrometry in the Identification of Impurities 100
- IV. NMR 126
- V. Case Studies 147
- VI. Summary 157 References 158

#### 4. Analytical Considerations for Genotoxic and Other Impurities

RODNEY L. PARSONS AND SCOTT A. MILLER

- I. Introduction 171
- II. Concept of GTI Relative to Standard Impurities and the Current Regulatory Thinking 172
- III. Viracept® GTI Contamination Issue 173
- IV. GTI Risk Assessment and Control Strategy Design 174
- V. Analytical Challenges 179
- VI. Summary and Conclusions 191 References 191

#### 5. Quality by Design and the Importance of PAT in QbD

ROBERT W. BONDI, Jr. AND JAMES K. DRENNEN, III

- I. Introduction 195
- II. The Role of PAT in QbD 200

# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

#### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

#### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

